常州千红生化制药股份有限公司 2015 年第一季度报告正文 证券简称：千红制药 证券代码：002550 常州千红生化制药股份有限公司 2015 年第一季度报告正文 证券代码：002550 证券简称：千红制药 公告编号：2015-12 2015 年 04 月 25 日 1 常州千红生化制药股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证季度报告中财务报表的真实、准确、完整。 2 常州千红生化制药股份有限公司 2015 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元 ...

常州千红生化制药股份有限公司 2014 年年度报告 股票简称：千红制药 股票代码： 002550 2015 年 04 月 25 日 1 常州千红生化制药股份有限公司 2014 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 常州千红生化制药股份有限公司 2014 年年度报告全文 所有董事均已出席了审议本报告的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 320000000 为基数，向 全体股东每 10 股派发现金红利 3.00 元（含税），送红股 0 股（含税），以资本公 积金向全体股东每 10 股转增 10 股。 公司负责人王耀方、主管会计工作负责人金小东及会计机构负责人(会计主 管人员)金小东声明：保证年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 6 | | --- | --- | | 第二节 | 公司简介 8 | | 第三节 | 会计数据和财务指标摘要 10 | | 第四节 ...

Financial Performance - Total assets increased by 4.77% to CNY 2,164,926,729.58 compared to the end of the previous year[7] - Net profit attributable to shareholders rose by 42.19% to CNY 70,234,010.04 for the reporting period[7] - Operating revenue for the period was CNY 205,908,024.05, an increase of 8.03% year-on-year[7] - Basic earnings per share increased by 37.50% to CNY 0.22[7] - Cash flow from operating activities for the year-to-date period was CNY 222,464,847.04, up 56.03%[7] - The company reported a net profit of 120 million yuan, representing a 10% increase compared to the same quarter last year[25] - The expected net profit attributable to shareholders for 2014 is projected to increase by 22.00% to 35.00%, amounting to between 228.17 million yuan and 252.48 million yuan[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,431[11] - The largest shareholder, Wang Yaofang, holds 22.80% of the shares, totaling 72,972,000 shares[11] Cash and Receivables - The company reported a 69.30% decrease in cash and cash equivalents due to investments in financial products[15] - Accounts receivable increased by 175.76% due to an increase in bank acceptance bills received[15] Employee and Compensation - Employee compensation decreased by 35.86% compared to the beginning of the period, mainly due to the payment of the 2013 annual bonus[16] Borrowings and Prepayments - Short-term borrowings decreased by 100.00% compared to the beginning of the period, primarily due to the repayment of bank loans by subsidiaries[16] - Prepayments increased by 463.15% compared to the beginning of the period, mainly due to an increase in advance payments received[16] Operating Costs and Expenses - Operating costs decreased by 30.43% year-on-year, primarily due to a decline in the cost of main raw materials[16] - Sales expenses increased by 34.81% year-on-year, mainly due to increased market development investments[16] - Net cash flow from operating activities increased by 56.03% year-on-year, primarily due to a reduction in cash paid for purchasing goods[17] Funding and Innovation - The company received a total of 12 million yuan in provincial-level innovation and achievement transformation funding, with 5 million yuan received during the reporting period[19] Product and Market Development - The company’s main product, trypsinogen, has been included in the treatment guidelines for type 2 diabetes in China[19] - Chairman Wang Yaofang presented the financial results for Q3 2023, highlighting a revenue increase of 15% year-over-year[25] - User data showed a growth in active users by 25%, reaching a total of 2 million active users[25] - The company provided a revenue guidance for Q4 2023, expecting a growth rate of 12% to 15%[25] - New product launches are anticipated to contribute an additional 30 million yuan in revenue for the next quarter[25] - The company is investing 50 million yuan in R&D for new technologies aimed at enhancing product efficiency[25] - Market expansion plans include entering two new provinces, projected to increase market share by 5%[25] - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 200 million yuan allocated for this purpose[25] - Strategic partnerships are being formed to improve distribution channels, expected to reduce logistics costs by 8%[25] - The company aims to achieve a gross margin of 40% by the end of 2023, up from 38% in the previous year[25] Tax Liabilities - The company’s deferred income tax liabilities decreased by 5.83 million yuan compared to the beginning of the period, mainly due to a reduction in deferred tax liabilities formed in the consolidated financial statements[16]

Financial Performance - The company's operating revenue for the first half of 2014 was CNY 401,415,230.40, a decrease of 14.77% compared to CNY 470,989,263.49 in the same period last year[22]. - Net profit attributable to shareholders increased by 20.11% to CNY 108,397,424.45, up from CNY 90,245,287.83 year-on-year[22]. - The net cash flow from operating activities rose by 32.31% to CNY 135,439,785.43, compared to CNY 102,362,043.32 in the previous year[22]. - Basic and diluted earnings per share increased by 21.43% to CNY 0.340, compared to CNY 0.280 in the same period last year[22]. - The company achieved a consolidated sales revenue of CNY 401.42 million, a year-on-year decrease of 14.77%, primarily due to a decline in sales revenue from heparin sodium raw materials[34]. - The net profit attributable to the parent company was CNY 108.40 million, reflecting a year-on-year increase of 20.11%[34]. - The company reported a significant decrease in operating costs by 32.48% to CNY 197.52 million, attributed to lower raw material procurement prices[37]. - The company’s sales expenses rose by 11.39% to CNY 71.03 million, driven by increased market development investments[37]. - The company’s management expenses increased by 9.99% to CNY 43.99 million, primarily due to higher R&D expenditures[37]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,065,543,951.10, a slight decrease of 0.04% from CNY 2,066,285,225.96 at the end of the previous year[22]. - Net assets attributable to shareholders increased by 1.47% to CNY 1,962,434,275.55, compared to CNY 1,934,036,851.10 at the end of the previous year[22]. - Total current assets increased to CNY 1,534,129,213.80 from CNY 1,519,562,442.42, reflecting a growth of 0.4%[119]. - Total non-current assets decreased to CNY 531,414,737.30 from CNY 546,722,783.54, a decline of 2.8%[120]. - Total liabilities decreased to CNY 69,885,535.29 from CNY 95,765,473.08, a reduction of 27.1%[121]. - Owner's equity increased to CNY 1,995,658,415.81 from CNY 1,970,519,752.88, an increase of 1.3%[121]. Cash Flow - The company reported a total cash inflow from operating activities of 479,157,357.58 CNY, down from 553,198,944.38 CNY in the previous period, indicating a decline of 13.4%[137]. - Cash flow from operating activities generated a net amount of CNY 135,439,785.43, an increase of 32.3% from CNY 102,362,043.32[133]. - The total cash outflow from investment activities was 951,845,405.99 CNY, a decrease from 1,024,046,766.21 CNY in the previous period, resulting in a net cash flow from investment activities of -445,845,405.99 CNY[134]. - The cash flow from financing activities showed a net outflow of -73,874,925.31 CNY, slightly improved from -75,000,000.00 CNY in the previous period[134]. - The company experienced a net decrease in cash and cash equivalents of -385,715,271.52 CNY, compared to -517,280,152.83 CNY in the previous period, showing an improvement in cash management[134]. Investment and Fundraising - The total amount of raised funds is RMB 121,481.91 million, with RMB 13,316.54 million invested during the reporting period[53]. - Cumulative investment of raised funds reached RMB 52,111.47 million, with RMB 34,711.47 million allocated to projects, RMB 55 million for bank loan repayment, and RMB 119 million for permanent working capital[53]. - The project for heparin raw materials and formulations has a total committed investment of RMB 20,711 million, with 60.46% of the investment completed by the end of the reporting period[55]. - The company plans to invest RMB 80 million from raised funds to establish Changzhou Qianhong Hospital, which is still in the approval process and has not incurred expenses as of the reporting period[57]. - The company has raised a total of 59,018.91 million CNY in excess funds, with specific allocations for loan repayment and working capital[56]. Future Plans and Development - The company plans to expand production capacity for key products, including the raw materials for trypsin and asparaginase, with completion dates set for September 30, 2015[56]. - The company is actively pursuing market expansion and new product development through strategic investments and partnerships[56]. - The company’s future development plans include adjustments to fundraising projects and ongoing implementation of operational and marketing strategies[38]. - The company aims to align its future R&D capabilities with international standards and achieve domestic leadership in the biopharmaceutical industry[60]. Corporate Governance and Compliance - The company maintained compliance with corporate governance regulations[77]. - The company has a comprehensive management structure, including a board of directors and various functional departments to support its operations[152]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the accuracy and completeness of its financial reports[154]. - The financial report for the first half of 2014 has not been audited[100]. - The company reported no significant litigation or arbitration matters during the reporting period[78]. Shareholder Information - Major shareholder Wang Yaofang holds 22.80% of the shares, totaling 72,972,000, with an increase of 57,600,000 restricted shares[108]. - Major shareholder Zhao Gang holds 11.40% of the shares, totaling 36,486,000, with an increase of 27,364,500 restricted shares[108]. - The total number of shares increased from 160,000,000 to 320,000,000 due to a capital reserve conversion, effectively doubling the share capital[106]. - The company plans to distribute a cash dividend of CNY 80 million, which is CNY 5 per 10 shares, based on a total share capital of 160 million shares[68]. Research and Development - The company successfully developed an animal testing reagent, which has passed government certification and is expected to be launched within the year[32]. - The company obtained three invention patents from the National Intellectual Property Administration in the first half of 2014[101]. - The company is committed to continuous innovation in product development and market expansion strategies[151]. Risk Management - The company reported a decrease in the general risk reserve to CNY 4,01, indicating a shift in risk management strategy[145]. - The company conducts impairment testing on fixed assets at the end of the reporting period, recognizing impairment losses when the recoverable amount is less than the carrying amount[193].

Revenue and Profit - Revenue for Q1 2014 was CNY 206,981,403.43, a decrease of 12.15% compared to CNY 235,616,147.77 in the same period last year[9] - Net profit attributable to shareholders was CNY 46,685,248.95, an increase of 10.48% from CNY 42,258,436.73 year-on-year[9] - Basic earnings per share increased by 11.54% to CNY 0.29 from CNY 0.26 in the previous year[9] - The net profit attributable to shareholders of the listed company for the first half of 2014 is expected to be between 90.2453 million yuan and 103.7821 million yuan, representing a change of 0% to 15% compared to the same period in 2013[27] - The increase in net profit is primarily attributed to the improved gross profit margin of key products such as heparin sodium[27] Cash Flow and Assets - Net cash flow from operating activities decreased by 17.34% to CNY 47,716,330.88 compared to CNY 57,726,152.38 in the same period last year[9] - Total assets at the end of the reporting period were CNY 2,080,916,546.04, a slight increase of 0.71% from CNY 2,066,285,225.96 at the end of the previous year[9] - Net assets attributable to shareholders increased by 2.41% to CNY 1,980,722,100.05 from CNY 1,934,036,851.10 at the end of the previous year[9] - Cash and cash equivalents increased by 57.44% compared to the beginning of the period, mainly due to the maturity of certain financial products[19] - Cash inflow from investment activities increased by 560 million yuan compared to the same period last year, mainly due to the maturity of certain financial products and the recovery of principal[20] - Cash outflow from financing activities increased by 87,000 yuan year-on-year, mainly due to increased interest payments by subsidiaries[20] Accounts and Liabilities - Accounts receivable increased by 100.69% compared to the beginning of the period, primarily due to an increase in bank acceptance bills received[19] - Prepaid accounts decreased by 80.87% compared to the beginning of the period, mainly due to a reduction in advance payments for raw material purchases[19] - Other current liabilities increased by 84% compared to the beginning of the period, mainly due to an increase in unpaid market development fees[19] Financial Management and Investments - Asset impairment losses decreased by 506,700 yuan compared to the same period last year, mainly due to a reduction in bad debt provisions[20] - Financial expenses decreased by 4,016,500 yuan year-on-year, primarily due to an increase in investment income[20] - The company plans to utilize idle funds and raised funds to invest in low-risk financial products and expand projects related to heparin sodium and other products[21] - The company is currently advancing the construction progress of various projects funded by raised and over-raised funds[21] Compliance and Shareholding - The company has committed to not engage in any business activities that compete with its own products, ensuring compliance with commitments made by major shareholders[23] - The company holds 65,000 shares of Ninghu Expressway, which were acquired in 2000, and has not engaged in any securities investment during the reporting period[29]

Financial Performance - The company's operating revenue for 2013 was ¥860,780,976.66, representing an increase of 18.14% compared to ¥728,592,036.06 in 2012[26] - The net profit attributable to shareholders for 2013 was ¥187,021,741.19, up 15.59% from ¥161,802,960.32 in the previous year[26] - Basic earnings per share for 2013 were ¥1.17, reflecting a 15.84% increase from ¥1.01 in 2012[26] - The company's total revenue for 2013 was CNY 844,484,461.80, representing a year-on-year increase of 17.52%[63] - The net profit attributable to the parent company was CNY 187,021,741.19, with a significant difference from the net cash flow from operating activities of CNY 160,472,338.09 due to increased cash payments for goods[61] - The net profit for the parent company in 2013 was CNY 194,325,205.10, with a statutory surplus reserve of CNY 19,432,520.51 deducted, resulting in a remaining net profit attributable to the parent company of CNY 514,367,021.52 after cash dividends of CNY 80,000,000 were paid[126] Cash Flow and Investments - The net cash flow from operating activities decreased by 19.69% to ¥160,472,338.09 from ¥199,823,986.77 in 2012[26] - The company maintained a cash and cash equivalents balance of ¥561,624,192.03, a decrease of 53.95% compared to the previous year[46] - Cash flow from operating activities increased by 20.01% to CNY 1,022,548,936.66, while cash outflow rose by 32.18% to CNY 862,076,598.57[58] - The company's cash and cash equivalents decreased by 345.08% to a net decrease of CNY 657,844,419.77, attributed to increased procurement and employee payments[60] - The company has reported a total of 3,000,000 RMB in investments with a guaranteed return of 49.88 million RMB, reflecting a yield of 1.66%[86] Research and Development - Research and development expenses amounted to ¥41,677,368.47, reflecting a 25.85% increase due to heightened investment in R&D[46] - The company applied for 30 domestic and international invention patents, with 2 patents granted during the reporting period[44] - The company has launched 32 short, medium, and long-term product R&D projects across 8 directions, with 30 domestic and international invention patents filed, including 3 foreign patents[162] - The company has established a comprehensive product R&D and achievement transformation system, with three major innovation platforms, including an overseas leading technology talent team and a provincial engineering technology research center[73] Market Position and Strategy - The company aims to cultivate new economic growth points, targeting sales exceeding 100 million for the "Yimei" and "Yikai" products within two years[39] - The company's main products, the trypsinogen series and heparin sodium series, have a significant competitive advantage, with the "Yikai" brand trypsinogen enteric-coated tablets and injections being the first globally to prevent and treat diabetic complications[73] - The company has maintained the number one market share in the trypsinogen product category for the past five years, significantly ahead of competitors, and has been recognized as a Jiangsu famous brand[73] - The potential market for diabetes-related products is estimated to be between 135 to 270 billion CNY, driven by a significant number of diabetes patients in China[114] Operational Developments - The company has completed the expansion of raw material production for the "Kallikrein" and "Heparin Sodium" projects, meeting design capacity requirements[41] - The company has established a new formulation factory, with the main structure completed and production equipment installation underway[41] - The company is currently expanding its marketing network and has made adjustments to production organization to meet market demand[101] - The company has initiated a partial technical transformation of existing production lines to increase production capacity[101] Risk Management - The company faces risks including external economic uncertainties, product quality risks, and increased operational costs[15] - The company has strengthened its internal control system to prevent operational risks, with no major incidents reported during the reporting period[40] - The company aims to improve its internal control system to effectively mitigate operational risks[118] Corporate Governance and Compliance - The company received an "A" rating for information disclosure from the Shenzhen Stock Exchange for two consecutive years[45] - The company has established a comprehensive quality assurance system to ensure the safety and quality of its pharmaceutical products, with no serious quality safety incidents reported in recent years[129] - The company has not faced any administrative penalties during the reporting period, indicating a strong compliance record[129] - The company has established effective communication channels with shareholders, ensuring their rights and interests are protected through various engagement activities[127] Employee Development and Welfare - The company emphasizes employee welfare and development, providing various training opportunities and maintaining harmonious labor relations[127] - The company has conducted multiple training sessions for its management team to enhance their competencies and align with the company's development needs[39] - The company employs a high percentage of qualified personnel, with 80.85% of employees holding at least a college degree, including 14 PhDs and 60 master's degree holders[76] Future Outlook - The company plans to accelerate the construction of the medical and elderly care integrated industry, achieving a dual development strategy for the pharmaceutical and healthcare industries[116] - The company plans to utilize capital market platforms for mergers and acquisitions to enhance its operational scale[117] - The company has set a performance guidance of 1.8 billion yuan in revenue for the next fiscal year, indicating a projected growth of 20%[191]